Nanobiotix S.A. (NANO.PA) Stock Analysis & Winston Score

Nanobiotix is a French biotech company that develops a new way to treat cancer using tiny particles called nanoparticles. Its main product, NBTXR3 (sold as Hepzato in some markets), is injected directly into tumors and activated by radiation therapy to destroy cancer cells more effectively. The company works with hospitals and cancer treatment centers, and its technology is being studied across many types of cancer. Nanobiotix earns revenue through partnerships and licensing deals rather than large-scale product sales, which explains its 100% gross margin but ongoing operating losses. It operates primarily in Europe and the United States, and has a significant collaboration with Bristol-Myers Squibb to explore combining NBTXR3 with immunotherapy drugs. The key growth driver is expanding clinical trial data across more cancer types and winning broader regulatory approvals, but the main risk is that the company continues to burn cash while waiting for those approvals to translate into meaningful commercial revenue.